Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
8
×
fda
8
×
life sciences
national blog main
national top stories
roche
8
×
biotech
boston blog main
boston top stories
san francisco top stories
deals
san francisco blog main
investing
national
new york top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
startups
takeda pharmaceutical
vertex pharmaceuticals
biogen
blueprint medicines
cancer immunotherapy
What
drug
fda
cancer
roche
roundup
ahead
approved
asco
bio
days
home
intended
medicine
medicines
new
patients
team
time
alliance
ambien
american
analytics
annual
approval
atrophy
attendees
attention
biofourmis
biotech
blueprint
branded
bristol
buy
calls
camp’s
candidate
cash
caught
causing
changing
Language
unset
Current search:
roche
×
" clinical trials "
×
fda
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More